Currently, six PD‐1 inhibitors, including nivolumab, pembrolizumab, cemiplimab, dostarlimab, toripalimab, and tislelizumab, have received United States Food and Drug Administration (U.S. FDA) approval for cancer treatment [3, 4, 5, 6, 7, 8]. This evidence concerns the gene PDCD1 and cancer.